Floatz logo

tr115

NK T-Cell Lymphoma

Tarapeutics Science Inc.Phase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

52 Active assets in the NK T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
PEGASPARGASE
CStone Pharmaceuticals
Phase 4BBB
DEXAMETHASONE
Mingzhi Zhang
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Centre, Singapore
Phase 4BBB
Tucidinostat
Ruijin Hospital
Phase 4BB
ETOPOSIDE
Tarapeutics Science Inc.
Phase 4BB

View all 50 →

Same molecule, other indications

tr115 is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant
B
Indicative ·
57 / 100
View asset →
non-Hodgkin lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →